Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial
ContributorsBurmester, Gerd R; Buttgereit, Frank; Bernasconi, Corrado; Álvaro-Gracia, Jose M; Castro, Nidia; Dougados, Maxime; Gabay, Cem; van Laar, Jacob M; Nebesky, Jan Michael; Pethoe-Schramm, Attila; Salvarani, Carlo; Donath, Marc Y; John, Markus R; SEMIRA collaborators
Published inThe Lancet, vol. 396, no. 10246, p. 267-276
Publication date2020
Abstract
Keywords
- Administration
- Intravenous
- Administration
- Oral
- Adult
- Aged
- Antibodies
- Monoclonal
- Humanized/administration & dosage/therapeutic use
- Arthritis
- Rheumatoid/drug therapy/ethnology
- Double-Blind Method
- Drug Administration Schedule
- Drug Therapy
- Combination
- Female
- France/epidemiology
- Germany/epidemiology
- Glucocorticoids/administration & dosage/adverse effects/therapeutic use
- Humans
- Injections
- Subcutaneous
- Italy/epidemiology
- Male
- Middle Aged
- Outcome Assessment
- Health Care
- Prednisone/administration & dosage/adverse effects/therapeutic use
- Remission Induction/methods
- Russia/epidemiology
- Serbia/epidemiology
- Tunisia/epidemiology
Affiliation entities
Research groups
Citation (ISO format)
BURMESTER, Gerd R et al. Continuing versus tapering glucocorticoids after achievement of low disease activity or remission in rheumatoid arthritis (SEMIRA): a double-blind, multicentre, randomised controlled trial. In: The Lancet, 2020, vol. 396, n° 10246, p. 267–276. doi: 10.1016/S0140-6736(20)30636-X
Main files (1)
Article (Published version)
Secondary files (1)
Appendix
Identifiers
- PID : unige:157869
- DOI : 10.1016/S0140-6736(20)30636-X
- PMID : 32711802
Journal ISSN0140-6736
